Reaves_Avery

C. S. Avery Reaves

Reaves_Avery

C. S. Avery Reaves

Partner

Boston + 1 617 526 6657

Avery Reaves is a member of the Corporate Practice where he counsels life sciences and technology companies on corporate and securities matters, with an emphasis on public offerings and public company counseling, mergers and acquisitions, and the representation of early-stage companies and investors in seed stage, venture capital, or other financing transactions.

Prior to joining WilmerHale, Mr. Reaves was an intern in the Public Corruption & Special Prosecutions Unit of the Criminal Division of the US Attorney’s Office in Boston. His previous experience includes working on corporate matters as a summer associate at WilmerHale in 2012 and another law firm in Boston in 2011.

Prior to law school, Mr. Reaves was an intern at Voxiva, a mobile health startup based in Washington DC, and a Venture Fellow with Richmond Global (formerly Richmond Management), an early-stage venture capital fund. Previously, Mr. Reaves was a consultant with The Boston Consulting Group where he worked in the finance, healthcare, retail, and transportation sectors.

Experience

  • Public Offerings

    • Thermo Fisher Scientific Inc. in its $1.725 billion public offering.
    • Ocular Therapeutix, Inc. in multiple public offerings including its $75 million initial public offering, its $101 million follow-on offering, its $25 million bought deal, and its $37 million confidentially marketed public offering.
    • Casa Systems, Inc. in its $175 million public offering by selling shareholders.
    • PTC Therapeutics, Inc. in its $100 million public offering.
    • Nightstar Therapeutics plc in its $83 million public offering.
    • Voyager Therapeutics, Inc. in its $62 million public offering.
    • AVEO Pharmaceuticals, Inc. in multiple public offerings including its $17 million confidentially marketed public offering and its $25 million common stock and warrant offering.
    • At-the-market offering programs on behalf of multiple public company clients including Voyager Therapeutics, Inc.; Ocular Therapeutix, Inc.; AVEO Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.; and Epizyme, Inc.

  • Mergers & Acquisitions

    • Thermo Fisher Scientific, Inc. in its $1.06 billion sale of its cell culture, gene modulation and magnetic beads businesses to GE Healthcare.
    • Cumberland Farms, Inc. in the approximately $800 million sale of its Gulf Oil and Assured Deal business to affiliates of ArcLight Capital Partners.
    • WEX Inc. in its $532 million acquisition of Evolution1, a leader in cloud-based technology and payment solutions in the healthcare industry.
    • A financial services company in its spinout of its private equity business.
    • A Flagship Pioneering portfolio company in its merger into Codiak Biosciences, Inc.
    • Sanbolic, Inc., an innovator and leader in workload-oriented storage virtualization technologies, in its acquisition by Citrix, Inc.
    • Tangoe, Inc. in its take-private, tender-offer sale to affiliates of Marlin Equity Partners.

  • Venture Capital and Other Financings

    • PTC Therapeutics, Inc. in its $288 million offering of convertible senior notes under Rule 144A.
    • Voyager Therapeutics, Inc. in its $50 million private placement of common stock.
    • Ocular Therapeutix, Inc. in its $37 million private placement of senior subordinated convertible notes.
    • A next-generation nuclear power company in its $25 million Series A financing.
    • A biotechnology company focusing on cellular medicines in its $18 million Series A financing.
    • A biotechnology company focusing on the microbiome in its $16 million Series A financing.
    • A global institutional investor in a $223 million preferred stock financing of Vets First Choice (f/k/a Direct Vet Marketing, Inc.).
    • A global institutional investor in a $125 million common stock financing of a private equity-backed healthcare company.
    • A global asset manager in a $23 million Series D financing of Nvest, Inc.
    • Flagship Pioneering, Spark Capital, General Catalyst, Samsara BioCapital and various other financial and strategic investors in numerous private placement financings.
    • Preferred stock financings on behalf of multiple private company clients including Celtaxsys, Inc.; 1366 Technologies Inc.; Soft Robotics Inc.; QD Vision, Inc.; and Embr Labs, Inc.
    • Convertible note and venture debt financings on behalf of multiple private company clients including Embr Labs, Inc.; Allena Pharmaceuticals, Inc.; and Benu Networks, Inc.

Recognition

  • Named to Boston Magazine’s Top Lawyers list in 2023 and 2024 in the area of corporate law.

Insights & News

View all of C. S. Avery's insights & news

Credentials

  • Education

    • JD, Harvard Law School, 2013

      Articles Editor and Deputy Managing Editor, Harvard Journal of Law & Public Policy

    • MBA, Finance and Health Care Management, The Wharton School, University of Pennsylvania, 2010

      with honors

    • AB, Political Science and Economics, Duke University, 2004

      magna cum laude

  • Admissions

    • Massachusetts

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel